Cargando…

A Single-Dose Combination Study with the Experimental Antimalarials Artefenomel and DSM265 To Determine Safety and Antimalarial Activity against Blood-Stage Plasmodium falciparum in Healthy Volunteers

Artefenomel and DSM265 are two new compounds that have been shown to be well tolerated and effective when administered as monotherapy malaria treatment. This study aimed to determine the safety, pharmacokinetics, and pharmacodynamics of artefenomel and DSM265 administered in combination to healthy s...

Descripción completa

Detalles Bibliográficos
Autores principales:	McCarthy, James S., Rückle, Thomas, Elliott, Suzanne L., Ballard, Emma, Collins, Katharine A., Marquart, Louise, Griffin, Paul, Chalon, Stephan, Möhrle, Jörg J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2019
Materias:	Clinical Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7187626/ https://www.ncbi.nlm.nih.gov/pubmed/31685476 http://dx.doi.org/10.1128/AAC.01371-19

Ejemplares similares

DSM265 at 400 Milligrams Clears Asexual Stage Parasites but Not Mature Gametocytes from the Blood of Healthy Subjects Experimentally Infected with Plasmodium falciparum
por: Collins, Katharine A., et al.
Publicado: (2019)

Antimalarial Activity of Artefenomel Against Asexual Parasites and Transmissible Gametocytes During Experimental Blood-Stage Plasmodium vivax Infection
por: Collins, Katharine A, et al.
Publicado: (2020)

Defining the Antimalarial Activity of Cipargamin in Healthy Volunteers Experimentally Infected with Blood-Stage Plasmodium falciparum
por: McCarthy, James S., et al.
Publicado: (2021)

Efficacy of OZ439 (artefenomel) against early Plasmodium falciparum blood-stage malaria infection in healthy volunteers
por: McCarthy, James S., et al.
Publicado: (2016)

Linking Murine and Human Plasmodium falciparum Challenge Models in a Translational Path for Antimalarial Drug Development
por: McCarthy, James S., et al.
Publicado: (2016)

Safety, Tolerability, Pharmacokinetics, and Antimalarial Activity of the Novel Plasmodium Phosphatidylinositol 4-Kinase Inhibitor MMV390048 in Healthy Volunteers
por: Sinxadi, Phumla, et al.
Publicado: (2020)

Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a/1b randomised study
por: McCarthy, James S, et al.
Publicado: (2017)

Antimalarial activity of artefenomel (OZ439), a novel synthetic antimalarial endoperoxide, in patients with Plasmodium falciparum and Plasmodium vivax malaria: an open-label phase 2 trial
por: Phyo, Aung Pyae, et al.
Publicado: (2016)

A Pilot Randomised Trial of Induced Blood-Stage Plasmodium falciparum Infections in Healthy Volunteers for Testing Efficacy of New Antimalarial Drugs
por: McCarthy, James S., et al.
Publicado: (2011)

Characterizing the Blood-Stage Antimalarial Activity of Tafenoquine in Healthy Volunteers Experimentally Infected With Plasmodium falciparum
por: Barber, Bridget E, et al.
Publicado: (2023)

Antimalarial activity of single-dose DSM265, a novel plasmodium dihydroorotate dehydrogenase inhibitor, in patients with uncomplicated Plasmodium falciparum or Plasmodium vivax malaria infection: a proof-of-concept, open-label, phase 2a study
por: Llanos-Cuentas, Alejandro, et al.
Publicado: (2018)

A Phase 1, Placebo-controlled, Randomized, Single Ascending Dose Study and a Volunteer Infection Study to Characterize the Safety, Pharmacokinetics, and Antimalarial Activity of the Plasmodium Phosphatidylinositol 4-Kinase Inhibitor MMV390048
por: McCarthy, James S, et al.
Publicado: (2020)

DSM265 for Plasmodium falciparum chemoprophylaxis: a randomised, double blinded, phase 1 trial with controlled human malaria infection
por: Sulyok, Mihály, et al.
Publicado: (2017)

Predicting Optimal Antimalarial Drug Combinations from a Standardized Plasmodium falciparum Humanized Mouse Model
por: Demarta-Gatsi, Claudia, et al.
Publicado: (2023)

Parasite Viability as a Measure of In Vivo Drug Activity in Preclinical and Early Clinical Antimalarial Drug Assessment
por: Radohery, Georges F. R., et al.
Publicado: (2022)

Artefenomel Regioisomer RLA-3107 Is a Promising Lead for the Discovery of Next-Generation Endoperoxide Antimalarials
por: Blank, Brian R., et al.
Publicado: (2023)

Chemoprotective Antimalarial Activity of P218 against Plasmodium falciparum: A Randomized, Placebo-Controlled Volunteer Infection Study
por: Chughlay, Mohamed Farouk, et al.
Publicado: (2021)

Monoclonal Antibodies That Recognize the Alkylation Signature of Antimalarial Ozonides OZ277 (Arterolane) and OZ439 (Artefenomel)
por: Jourdan, Joëlle, et al.
Publicado: (2015)

Population Pharmacokinetics and Pharmacodynamics of Chloroquine in a Plasmodium vivax Volunteer Infection Study
por: Abd‐Rahman, Azrin N., et al.
Publicado: (2020)

Preclinical Antimalarial Combination Study of M5717, a Plasmodium falciparum Elongation Factor 2 Inhibitor, and Pyronaridine, a Hemozoin Formation Inhibitor
por: Rottmann, Matthias, et al.
Publicado: (2020)

Pharmacokinetic/pharmacodynamic modelling of the antimalarial effect of Actelion‐451840 in an induced blood stage malaria study in healthy subjects
por: Krause, Andreas, et al.
Publicado: (2016)

Comparison of the susceptibility of Plasmodium knowlesi and Plasmodium falciparum to antimalarial agents
por: van Schalkwyk, Donelly A, et al.
Publicado: (2017)

Antimalarials increase vesicle pH in Plasmodium falciparum
Publicado: (1985)

Validation of Plasmodium falciparum deoxyhypusine synthase as an antimalarial target
por: Aroonsri, Aiyada, et al.
Publicado: (2019)

Extrachromosomal DNA amplicons in antimalarial‐resistant Plasmodium falciparum
por: McDaniels, Jennifer M., et al.
Publicado: (2020)

Plasmodium falciparum Nicotinamidase as A Novel Antimalarial Target
por: Donu, Dickson, et al.
Publicado: (2022)

Lipid Compositions in Infant Formulas Affect the Solubilization of Antimalarial Drugs Artefenomel (OZ439) and Ferroquine during Digestion
por: Salim, Malinda, et al.
Publicado: (2020)

Safety and parasite clearance of artemisinin-resistant Plasmodium falciparum infection: A pilot and a randomised volunteer infection study in Australia
por: Watts, Rebecca E., et al.
Publicado: (2020)

Population Pharmacokinetics of Tafenoquine, a Novel Antimalarial
por: Thakkar, Nilay, et al.
Publicado: (2018)

Plasmodium falciparum merozoite invasion ligands, linked antimalarial resistance loci and ex vivo responses to antimalarials in The Gambia
por: Mbye, Haddijatou, et al.
Publicado: (2022)

Sensitivity of Plasmodium falciparum to Antimalarial Drugs in Hainan Island, China
por: Wang, Shan-Qing, et al.
Publicado: (2015)

The impact of antimalarial resistance on the genetic structure of Plasmodium falciparum in the DRC
por: Verity, Robert, et al.
Publicado: (2020)

Robenidine Analogues Are Potent Antimalarials in Drug-Resistant Plasmodium falciparum
por: Krollenbrock, Alina, et al.
Publicado: (2021)

Susceptibility of Ugandan Plasmodium falciparum Isolates to the Antimalarial Drug Pipeline
por: Kreutzfeld, Oriana, et al.
Publicado: (2023)

Haematological response in experimental human Plasmodium falciparum and Plasmodium vivax malaria
por: Woolley, Stephen D., et al.
Publicado: (2021)

Retrospective Analysis Using Pharmacokinetic/Pharmacodynamic Modeling and Simulation Offers Improvements in Efficiency of the Design of Volunteer Infection Studies for Antimalarial Drug Development
por: Andrews, Kayla Ann, et al.
Publicado: (2020)

In Vitro Antimalarial Activity of Inhibitors of the Human GTPase Rac1
por: Parapini, Silvia, et al.
Publicado: (2022)

Targeting Plasmodium falciparum Hsp90: Towards Reversing Antimalarial Resistance
por: Shahinas, Dea, et al.
Publicado: (2013)

Isoxazolopyrimidine-Based Inhibitors of Plasmodium falciparum Dihydroorotate Dehydrogenase with Antimalarial Activity
por: Kokkonda, Sreekanth, et al.
Publicado: (2018)

Genomic Epidemiology of Antimalarial Drug Resistance in Plasmodium falciparum in Southern China
por: Huang, Fang, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_43vaf609nogmu24aggcksvienq